Across TCGA pan-cancer cohorts, ERCC6L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ERCC6L data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ERCC6L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ERCC6L expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

OV, LSCC, and LUAD are the cancer types where ERCC6L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.779	1.000	.028	16	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.632	.007	11	view →
LUAD	DFS	Median	All	0.677	0.842	.007	4	view →
CCRCC	DFS	Median	III,IV	0.193	0.793	.038	2	view →
PDAC	DFS	Tertile	All	0.829	1.000	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ERCC6L tumor-vs-normal RNA expression · all ERCC6L data types